Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics Inc. (LUCD)
:LUCD
LUCD Stock Chart & Stats
$1.25
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.25
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.75 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.49M
Market Cap
$166.05M
Enterprise Value$164.69M
Total Cash (Recent Filing)$31.12M
Total Debt (Recent Filing)$27.55M
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 17, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding137,227,500
10 Day Avg. Volume1,382,728
30 Day Avg. Volume1,488,760
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.67
Price to Sales (P/S)9.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue37.77
Enterprise Value/Gross Profit-58.71
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$3.75Price Target Upside200.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial OutlookCurrent valuation attractive: maintaining BUY rating, but raising 12-month price target to $8.00 from $7.75 based on a NPV analysis, representing significant upside from the current share price.
Market PotentialThe estimated addressable domestic market opportunity for EsoGuard is ~$2 billion based on tens of millions of U.S. patients with gastroesophageal reflux disease (GERD).
Regulatory ApprovalsLucid is one step closer to receiving Medicare coverage for EsoGuard, which gives confidence in revenue estimates.
Bears Say
Commercialization ChallengesLucid's devices still have long commercialization and growth challenges ahead, but the ~billion dollars market potential presents high rewards for the risks.
Operational RisksLucid plans to advance commercialization of its 2 main products (EsoGuard and EsoCheck) as well as gain additional regulatory approvals (expand usage and insurance and government coverage especially for Medicare).
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.75 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $166.05M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 23 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on Aug 13, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.014.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.1.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 137,227,500 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (200.00% Upside)
$3.75 (200.00% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.86%
12-Months-Change
Fundamentals
Return on Equity
-463.56%
Trailing 12-Months
Asset Growth
13.36%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics (LUCD) is a medical diagnostics company focused on developing and commercializing innovative solutions for the early detection and prevention of gastrointestinal diseases, particularly esophageal cancer. The company operates primarily in the healthcare sector, leveraging its proprietary technology to provide non-invasive diagnostic tests that aid physicians in identifying precancerous conditions. Its core product, the EsoGuard test, is designed to analyze cells from the esophagus to detect early signs of cancer and other related disorders, facilitating timely intervention and improving patient outcomes.
LUCD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including significant revenue growth, successful partnerships, and progress toward Medicare coverage. However, challenges remain in terms of revenue recognition and high operational costs. The sentiment is cautiously optimistic with a focus on achieving Medicare coverage as a key milestone.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$3.75
▲(200.00% Upside)
Technical Analysis
Ownership Overview
2.41% Insiders
3.62% Mutual Funds
0.70% Other Institutional Investors
89.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---